This section features all recent CSL Behring news releases. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.
The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.
CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved the use of Berinert [C1 Esterase Inhibitor (Human)], its therapy for treating Hereditary Angioedema (HAE) attacks, for use in pediatric patients.
CSL Behring supports HAE Day thru our continued partnership with HAEi & global awareness event sponsorships.